|
1
|
Niccolai E, Taddei A, Prisco D and Amedei
A: Gastric cancer and the epoch of immunotherapy approaches. World
J Gastroenterol. 21:5778–5793. 2015.PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang X, Cai H, Liang Y, Chen L, Wang X, Si
R, Qu K, Jiang Z, Ma B, Miao C, et al: Inhibition of c-Myc by
let-7b mimic reverses mutidrug resistance in gastric cancer cells.
Oncol Rep. 33:1723–1730. 2015.PubMed/NCBI
|
|
4
|
Ni P, Xu W, Zhang Y, Chen Q, Li A, Wang S,
Xu S and Zhou J: TXNL1 induces apoptosis in cisplatin resistant
human gastric cancer cell lines. Current Cancer Drug Targets.
14:850–859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fan K, Fan D, Cheng LF and Li C:
Expression of multidrug resistance-related markers in gastric
cancer. Anticancer Res. 20:4809–4814. 2000.PubMed/NCBI
|
|
6
|
Hong L, Piao Y, Han Y, Wang J, Zhang X, Du
Y, Cao S, Qiao T, Chen Z and Fan D: Zinc ribbon domain-containing 1
(ZNRD1) mediates multidrug resistance of leukemia cells through
regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther.
4:1936–1942. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Owona BA and Schluesener HJ: Molecular
insight in the multifunctional effects of oridonin. Drugs R D.
15:233–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie
J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a
diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion
protein and shows potent antitumor activity with low adverse
effects on t(8;21) leukemia in vitro and in vivo. Blood.
109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu B, Shen W, Liu X, Zhang T, Ren J, Fan Y
and Xu J: Oridonin inhibits BxPC-3 cell growth through cell
apoptosis. Acta Biochim Biophys Sin (Shanghai). 47:164–173. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Wang Y, Wang S, Gao Y, Zhang X and
Lu C: Oridonin phosphate-induced autophagy effectively enhances
cell apoptosis of human breast cancer cells. Med Oncol. 32:3652015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen RY, Xu B, Chen SF, Chen SS, Zhang T,
Ren J and Xu J: Effect of oridonin-mediated hallmark changes on
inflammatory pathways in human pancreatic cancer (BxPC-3) cells.
World J Gastroenterol. 20:14895–14903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang YY, Lv YF, Lu L and Cai L: Oridonin
inhibits mTOR signaling and the growth of lung cancer tumors.
Anticancer Drugs. 25:1192–1200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Z and Chen Y: Oridonin, a promising
antitumor natural product in the chemotherapy of hematological
malignancies. Curr Pharm Biotechnol. 15:1083–1092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu
YP, Yu XJ, Zhang XD, Ming PH, Zhou GB and Huang L: The natural
compound magnolol inhibits invasion and exhibits potential in human
breast cancer therapy. Sci Rep. 3:30982013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P and Huang L:
Homoharringtonine induces apoptosis and inhibits STAT3 via
IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer
cells. Sci Rep. 5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou CC, Yang JS, Lu HF, Ip SW, Lo C, Wu
CC, Lin JP, Tang NY, Chung JG, Chou MJ, et al: Quercetin-mediated
cell cycle arrest and apoptosis involving activation of a caspase
cascade through the mitochondrial pathway in human breast cancer
MCF-7 cells. Arch Pharm Res. 33:1181–1191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Radisavljevic Z: AKT as locus of cancer
multidrug resistance and fragility. J Cell Physiol. 228:671–674.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang
Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET
oncoprotein is associated with tumor progression and poor prognosis
in human non-small cell lung cancer. Oncotarget. 6:14913–14925.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khanna A and Pimanda JE: Clinical
significance of cancerous inhibitor of protein phosphatase 2A in
human cancers. Int J Cancer. 138:525–532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang JL, Liu XZ, Wang PY, Chen GW, Jiang
Y, Qiao SK, Zhu J, Wang X, Pan YS and Liu YC: Targeting HCCR
expression resensitizes gastric cancer cells to chemotherapy via
down-regulating the activation of STAT3. Sci Rep. 6:241962016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Simonian PL, Grillot DA and Nuñez G: Bcl-2
and Bcl-XL can differentially block chemotherapy-induced cell
death. Blood. 90:1208–1216. 1997.PubMed/NCBI
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicholson DW: Caspase structure,
proteolytic substrates, and function during apoptotic cell death.
Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Z, Wang J, Tang J, Liu X, Zhong Q,
Wang F, Hu W, Yuan Z, Nie C and Wei Y: JNK- and Akt-mediated Puma
expression in the apoptosis of cisplatin-resistant ovarian cancer
cells. Biochem J. 444:291–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hasegawa M, Ishiguro K, Ando T and Goto H:
Geranylgeranylacetone attenuates cisplatin-induced reductions in
cell viability by suppressing the elevation of intracellular p53
content without heat shock protein induction. Nagoya J Med Sci.
74:123–131. 2012.PubMed/NCBI
|
|
27
|
Alcantara LM, Kim J, Moraes CB, Franco CH,
Franzoi KD, Lee S, Freitas-Junior LH and Ayong LS:
Chemosensitization potential of P-glycoprotein inhibitors in
malaria parasites. Exp Parasitol. 134:235–243. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo L, Sun YJ, Yang L, Huang S and Wu YJ:
Avermectin induces P-glycoprotein expression in S2 cells via the
calcium/calmodulin/NF-kappaB pathway. Chem Biol Interact.
203:430–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ying L, Zu-An Z, Qing-Hua L, Qing-Yan K,
Lei L, Tao C and Yong-Ping W: RAD001 can reverse drug resistance of
SGC7901/DDP cells. Tumour Biol. 35:9171–9177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kornmann M, Arber N and Korc M: Inhibition
of basal and mitogen-stimulated pancreatic cancer cell growth by
cyclin D1 antisense is associated with loss of tumorigenicity and
potentiation of cytotoxicity to cisplatinum. J Clin Invest.
101:344–352. 1998. View
Article : Google Scholar : PubMed/NCBI
|
